Tiane Dai is a Nephrology physician affiliated with University of California, Los Angeles. OpenAlex indexes 47 publications with 1,220 citations (h-index 16).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
21840 Normandie Ave Ste 700
Torrance, CA 905022047
Telephone
310-222-5026Registry record last updated 15 Jul 2019.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20258 payments
- Calliditas Therapeutics US Inc.Program year20251 payment
- Aurinia Pharma U.S., Inc.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
44.8%Calcium channel blocker18.1%Nifedipine Er61%Amlodipine Besylate25%Diltiazem 12hr Er14%Part D<11 patientsAngiotensin receptor blocker (ARB)8%Losartan Potassium100%Part D<11 patients+ 4 more classes in this area
Other
20%Phosphate Binder14.3%Sevelamer Carbonate69%Sevelamer Hcl31%Part D<11 patientsDrugs for treatment of hyperkalemia and hyperphosphatemia5.6%Lokelma100%Part D<11 patientsBlood & clotting
17.6%Solutions for parenteral nutrition14.6%Calcium Acetate100%Part D≥20 patientsP2Y12 inhibitor3.1%Clopidogrel100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The Association of Fibrate Use with Kidney Outcomes and Mortality
Clinical Journal of the American Society of Nephrology
2025 - Evolution of continuous renal replacement therapy scenarios and the rise of anticoagulant-free continuous veno-venous hemodiafiltration
Current Opinion in Nephrology & Hypertension
2025 - Beyond Parathyroid: A Mystery of Refractory Hypercalcemia Requiring Hemodialysis
Journal of the American Society of Nephrology
2025 - Favorable Long-Term Outcome in Steroid- and Cyclosporine-Resistant, Tacrolimus-Responsive FSGS
Journal of the American Society of Nephrology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Gregg Fonarow, MD
University of California, Los Angeles
Dennis Slamon, MD
University of California, Los Angeles
Tomas Ganz, MD
University of California, Los Angeles
Richard Casaburi, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”